<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616507</url>
  </required_header>
  <id_info>
    <org_study_id>IRB109-196-A</org_study_id>
    <nct_id>NCT05616507</nct_id>
  </id_info>
  <brief_title>Oligo-Fucoidan Decrease Lung Radiation Damage</brief_title>
  <acronym>FIRILI</acronym>
  <official_title>A Phase II Trial of Oligo-Fucoidan in Radiation Induced Ling Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fucoidan is FDA approved and in common use for treatment of angina. These studies will&#xD;
      advance that work to human use. Successful mitigation of lung radiation damage and heart&#xD;
      toxicity will improve the quality of life in veterans and non-veterans who are treated for&#xD;
      lung cancer by radiation, and may also improve cure rates of radiation therapy for lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project will test the effect of Fucoidan to mitigate the lung damage that can occur as a&#xD;
      side effect of radiation therapy for lung cancer. Thousands of veterans develop lung cancer&#xD;
      every year, and are treated by radiation therapy. Studies of lung radiation injury in&#xD;
      laboratory animals show that with Fucoidan, investigators can significantly reduce the&#xD;
      severity of lung fibrosis and heart toxicity.1,2 Fucoidan is FDA approved and in common use&#xD;
      for treatment of angina. These studies will advance that work to human use. Successful&#xD;
      mitigation of lung radiation damage and heart toxicity will improve the quality of life in&#xD;
      veterans and non-veterans who are treated for lung cancer by radiation, and may also improve&#xD;
      cure rates of radiation therapy for lung cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2022</start_date>
  <completion_date type="Anticipated">December 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study Type : Interventional (Clinical Trial) Actual Enrollment : 100 participants Allocation: Randomized Intervention Model: Parallel Assignment, matching sex, age, and performance status</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Radiation Pneumonitis</measure>
    <time_frame>6 months</time_frame>
    <description>The clinical occurrence and grade of radiation pneumonitis, by National Cancer Institute Common Terminology Criteria Adverse Event grading ( NCI CTCAE) (Grade 0-5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Radiation Pneumonitis</measure>
    <time_frame>one year</time_frame>
    <description>The clinical occurrence and grade of radiation pneumonitis, by National Cancer Institute Common Terminology Criteria Adverse Event grading ( NCI CTCAE) (Grade 0-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Radiation Pneumonitis</measure>
    <time_frame>two year</time_frame>
    <description>The clinical occurrence and grade of radiation pneumonitis, by National Cancer Institute Common Terminology Criteria Adverse Event grading ( NCI CTCAE)(Grade 0-5)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Radiation Toxicity</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fucoidan</intervention_name>
    <description>It is recommended to consume on an empty stomach, 2 servings per day, a total of 8 tablets, which can be eaten at one time or in divided doses. If it is difficult to swallow, the powder in the capsule can also be taken out and mixed with food or liquid food.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages Eligible for Study: 20-90 years old&#xD;
&#xD;
          2. Men and women undergoing radiation therapy for lung cancer，no matter the radiation&#xD;
             therapy is for curing or for palliating.&#xD;
&#xD;
          3. Karnofsky performance status，KPS &gt; 70&#xD;
&#xD;
          4. Absolute Neutrophils &gt; 1000/mm^3&#xD;
&#xD;
          5. Platelets &gt; 75,000/mm^3&#xD;
&#xD;
          6. Hematocrit &gt; 25%.&#xD;
&#xD;
          7. Liver and kidney function tests will be within normal range&#xD;
&#xD;
          8. Baseline blood pressure will be systolic &gt; 110 mmHg sitting&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who get lung cancer but no need or without the willingness of radiation&#xD;
             therapy&#xD;
&#xD;
          2. Patients who are taking antiHTN drugs&#xD;
&#xD;
          3. Women of pregnant, lactating, childbearing potential, or with the intention of&#xD;
             becoming pregnant&#xD;
&#xD;
          4. Patients who are presently participating in another clinical study (except for&#xD;
             follow-up surveys for study outcomes)&#xD;
&#xD;
          5. Patients who are judged to be ineligible for study entry by the investigator or&#xD;
             subinvestigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>20-90</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Szu-Yuan Wu</last_name>
    <role>Study Director</role>
    <affiliation>Asia University, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Szu-Yuan Wu</last_name>
    <phone>+886910603955</phone>
    <email>szuyuanwu5399@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Szu-Yuan Wu</name>
      <address>
        <city>Taipei</city>
        <state>Please Select</state>
        <zip>116</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Szu-Yuan Wu</last_name>
      <phone>0910603955</phone>
      <email>szuyuanwu5399@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2022</verification_date>
  <study_first_submitted>April 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 13, 2022</last_update_submitted>
  <last_update_submitted_qc>November 13, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation pneumonitis</keyword>
  <keyword>fucoidan</keyword>
  <keyword>radiation induced cardiac toxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fucoidan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study completed</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>data will become available on April 30 2022.</ipd_time_frame>
    <ipd_access_criteria>requirement with official application</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

